Key result
Intravenous E-3174 reduced supine diastolic blood pressure compared to placebo, with a maximum hypotensive effect at 8 hours.
Why the study?
Does intravenous E-3174 reduce blood pressure in patients with essential hypertension?
RCT
double-blind
randomized
Does intravenous E-3174 reduce blood pressure in patients with essential hypertension?
Intravenous E-3174, the active metabolite of losartan, effectively reduces blood pressure in patients with essential hypertension without significant acute adverse effects.
Answers are grounded in this paper and cite their sources.
IV E-3174 supports acute BP reduction in essential hypertension; extends losartan metabolite efficacy to intravenous administration in RCT.
Losartan potassium (DuP 753), an orally active angiotensin II receptor antagonist, is metabolized to a more potent active metabolite, E-3174, which contributes to losartan's long duration of action. The acute pharmacodynamic actions of intravenous (i.v.) E-3174 (20 mg infused over 4 h) were compared to placebo (vehicle) in two groups of patients with essential hypertension. Patients with supine diastolic blood pressure (SuDBP) of 100 to 120 mm Hg entered a 2-day inpatient phase and received vehicle on day 1. Patients with SuDBP > or = 95 mm Hg were randomized to double-blind treatment the next day. E-3174 significantly (P < .05) reduced SuDBP compared to placebo, beginning at approximately 100 min after the start of the infusion, with a maximum hypotensive effect at 8 h. Supine systolic blood pressure was also reduced by E-3174. Supine and standing heart rates did not differ between treatments. Mean E-3174 plasma levels were 324.6 ng/mL at 20 min and approximately 1000 ng/mL at the end of the 4-h infusion; during this time there was a modest decrease in blood pressure. Following the infusion, the relationship between plasma E-3174 levels and SuDBP was confounded by much larger decreases in blood pressure, which occurred as plasma drug concentrations declined. Urinary excretions of sodium, potassium, or chloride were not significantly altered by E-3174 nor was the fractional excretion of uric acid significantly different between groups. There were no drug-related or serious adverse experiences and no patient discontinued treatment due to an adverse experience.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Sweet et al. (1994) conducted an RCT in essential hypertension. Intravenous E-3174 vs. placebo was evaluated on supine diastolic blood pressure (SuDBP) (p=< .05). Intravenous E-3174 reduced supine diastolic blood pressure compared to placebo, with a maximum hypotensive effect at 8 hours.
Synapse has enriched 10 related papers. Consider them for comparative context: